Data to be Presented Regarding Impact on Sleep Quality and
Nasal Symptom Relief at 24 Hours Post Dose in Patients with
Seasonal and Perennial Allergic Rhinitis

JERUSALEM--(BUSINESS WIRE)--Feb 22, 2013 - Teva Pharmaceutical
Industries Ltd. announced today that additional data analyzed from
the Phase III clinical program for QNASL®
(beclomethasone dipropionate) Nasal Aerosol will be presented at
the 2013 Annual Meeting of the American Academy of Allergy, Asthma
and Immunology (AAAAI) in San Antonio, Texas on February 22-26,
2013. QNASL® is a nonaqueous or
“dry-mist” nasal aerosol corticosteroid that treats
seasonal and year-round nasal allergy symptoms in adults and
adolescents 12 years of age and older.

Data will be presented at the meeting regarding the efficacy of
QNASL® in treating the symptoms associated with
seasonal and perennial allergic rhinitis (SAR and PAR), including
the drug's potential quality of life benefits and sleep quality
improvement. Furthermore, the data also demonstrated nasal symptom
relief in patients with SAR and PAR who received treatment with
QNASL® 24 hours after dosing.

On March 23, 2012, the U.S. Food and Drug Administration (FDA)
approved QNASL®. The product became available by
prescription in April 2012, making it the first marketed nonaqueous
or “dry-mist” nasal aerosol product in a category that
reports annual sales of $2.5 billion. QNASL® is
delivered as a once-daily, nonaqueous aerosol that uses an
environmentally friendly propellant (HFA) and contains a built-in
dose counter.

“These studies are important because the impact of
allergic rhinitis on a patient's quality of life is significant.
Nasal allergies are often associated with burdensome symptoms such
as nasal congestion, sneezing, and itchy and runny nose, which may
contribute to disrupted sleep and impaired daytime
activities,” said Dr. Eli Meltzer, Senior Associate, Allergy
& Asthma Medical and Research Center, A.P.C. and Clinical
Professor, Department of Pediatrics, Division of Allergy and
Immunology, University of California, San Diego. “These
findings reinforce the efficacy of QNASL® to treat
nasal symptoms and to provide sustained relief from burden of
allergic rhinitis.”

The following QNASL® data will be presented
during poster sessions on Sunday, February 24 from 9:45 –
10:45 a.m. (CST) in Hall C (street level) of the Henry B. Gonzalez
Convention Center at the AAAAI Annual Meeting:

“The data to be presented at AAAAI further explored the
safety and efficacy of QNASL® and demonstrated its
ability to benefit patients suffering from seasonal and year-round
nasal allergies,” said Tushar Shah, MD, Senior Vice
President, Teva Global Respiratory Research and Development.
“Teva Respiratory is committed to offering patients treatment
options that deliver continued relief of bothersome nasal allergy
symptoms and help improve their quality of life.”

ABOUT ALLERGIC RHINITIS

Allergic rhinitis (AR) is a chronic inflammatory disease
characterized by symptoms such as sneezing, nasal itch, runny nose
and nasal congestion. For many AR patients, nasal congestion or a
stuffy nose may be the most frequent and bothersome symptom.
According to a recent survey, patients suffer considerable
discomfort during allergy attacks, such that nearly two out of five
(38 percent) said their discomfort was not tolerable without
relief. Based on the available evidence, intranasal corticosteroids
are the most effective treatment options for patients with AR.

According to the American Academy of Allergy, Asthma and
Immunology (AAAAI), the prevalence of AR in the U.S. has increased
during the past three decades; it is recently estimated at 20
percent in the general adult and adolescent populations. Of those
Americans affected with AR, approximately 20 percent have SAR, 40
percent have perennial allergic rhinitis (PAR) and 40 percent have
a combination of the two (i.e., PAR with seasonal exacerbation)
depending on the allergen sensitivity. Because of its prevalence
and health effect, AR is associated with considerable direct and
indirect costs. An estimate of $11.2 billion in healthcare costs,
12 million physician office visits, 2 million days of school
absences and 3.5 million lost work days per year are attributed to
AR. In addition, the presence of co-morbidities such as asthma and
sinusitis further increase AR-related treatment costs.

About QNASL®(BECLOMETHASONE DIPROPIONATE)

QNASL® Nasal Aerosol is a prescription
corticosteroid medication that treats seasonal nasal and year-round
nasal allergy symptoms in adults and adolescents 12 years of age
and older. It is administered as a nonaqueous or "dry-mist”
spray delivered by hydrofluoroalkane (HFA), an environmentally
friendly propellant. QNASL® (beclomethasone
dipropionate) Nasal Aerosol contains beclomethasone dipropionate,
which is a man-made (synthetic) corticosteroid. Corticosteroids are
natural substances found in the body that reduce inflammation. When
QNASL® (beclomethasone dipropionate) Nasal Aerosol
is sprayed into the nose, it helps reduce the nasal symptoms of
allergic rhinitis (inflammation of the lining of the nose), such as
stuffy nose, runny nose, itching and sneezing. It is not known
whether QNASL® (beclomethasone dipropionate) Nasal
Aerosol is safe and effective in children under 12 years of
age.

IMPORTANT SAFETY
INFORMATION

In clinical studies, nosebleeds and nose ulcers were more common
in patients treated with QNASL Nasal Aerosol than patients who
received placebo. Some nosebleeds were more severe in patients
treated with QNASL Nasal Aerosol than in patients who received
placebo. Tell your healthcare provider if you start to have
nosebleeds or nasal ulcers after using QNASL® Nasal
Aerosol.

Thrush (Candida), a fungal infection in your nose, mouth,
or throat may occur. Tell your healthcare provider if you have any
redness or white colored patches in your mouth or throat.

You should avoid using QNASL® Nasal Aerosol until
your nose is healed if you have a sore in your nose, you have had
recent surgery on your nose or if your nose has been injured,
because QNASL® Nasal Aerosol may cause slow wound
healing.

Some people who use corticosteroids may have eye problems such
as increased pressure in the eye (glaucoma) or cataracts. If you
have a history of glaucoma or cataracts or have a family history of
eye problems, you should have regular eye exams while you use
QNASL® Nasal Aerosol.

Serious allergic reactions can happen in people taking
QNASL® Nasal Aerosol. Stop using
QNASL® Nasal Aerosol and call your healthcare
provider right away or get emergency help if you experience
shortness of breath or trouble breathing, skin rash, redness,
swelling, severe itching, or swelling of your lips, tongue or
face.

People are more likely to get infections if they have immune
system problems or use drugs, including corticosteroids, which may
weaken the body's ability to fight infections. Avoid contact with
people who have infections like chickenpox or measles while using
QNASL® Nasal Aerosol.

Speak to your healthcare provider before using
QNASL® Nasal Aerosol if you have tuberculosis or
untreated fungal, bacterial, or viral infections, or eye infections
caused by herpes. Symptoms of an infection include: fever, pain,
aches, chills, feeling tired, nausea and vomiting.

A condition in which the adrenal glands do not make enough
steroid hormones may occur. Symptoms can include tiredness,
weakness, dizziness, nausea and vomiting. Tell your healthcare
provider if you experience these symptoms.

Children taking QNASL® (beclomethasone
dipropionate) Nasal Aerosol should have their growth checked
regularly, since corticosteroids may slow growth in children.

The most common side effects with QNASL® Nasal
Aerosol are nasal discomfort, nosebleeds, and headache.

Tell your healthcare provider if you have any side effect that
bothers you or that does not go away.

These are not all of the possible side effects of
QNASL® (beclomethasone dipropionate) Nasal Aerosol.
For more information, ask your healthcare provider or
pharmacist.

You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit
www.fda.gov/medwatch, or call 1-800-FDA-1088.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading
global pharmaceutical company, committed to increasing access to
high-quality healthcare by developing, producing and marketing
affordable generic drugs as well as innovative and specialty
pharmaceuticals and active pharmaceutical ingredients.
Headquartered in Israel, Teva is the world's leading generic drug
maker, with a global product portfolio of more than 1,000 molecules
and a direct presence in about 60 countries. Teva's branded
businesses focus on CNS, oncology, pain, respiratory and women's
health therapeutic areas as well as biologics. Teva currently
employs approximately 46,000 people around the world and reached
$20.3 billion in net revenues in 2012.

This release contains forward-looking statements, which
express the current beliefs and expectations of management. Such
statements are based on management's current beliefs and
expectations and involve a number of known and unknown risks and
uncertainties that could cause our future results, performance or
achievements to differ significantly from the results, performance
or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to
such differences include risks relating to: our ability to develop
and commercialize additional pharmaceutical products, competition
for our innovative products, especially Copaxone® (including
competition from innovative orally-administered alternatives, as
well as from potential generic equivalents), competition for our
generic products (including from other pharmaceutical companies and
as a result of increased governmental pricing pressures),
competition for our specialty pharmaceutical businesses, our
ability to achieve expected results through our innovative R&D
efforts, the effectiveness of our patents and other protections for
innovative products, decreasing opportunities to obtain U.S. market
exclusivity for significant new generic products, our ability to
identify, consummate and successfully integrate acquisitions, the
extent to which any manufacturing or quality control problems
damage our reputation for high quality production and require
costly remediation, our potential exposure to product liability
claims to the extent not covered by insurance, increased government
scrutiny in both the U.S. and Europe of our agreements with brand
companies, potential liability for sales of generic products prior
to a final resolution of outstanding patent litigation, including
that relating to the generic version of Protonix®, our exposure
to currency fluctuations and restrictions as well as credit risks,
the effects of reforms in healthcare regulation and pharmaceutical
pricing and reimbursement, any failures to comply with complex
Medicare and Medicaid reporting and payment obligations,
governmental investigations into sales and marketing practices
(particularly for our specialty pharmaceutical products),
uncertainties surrounding the legislative and regulatory pathway
for the registration and approval of biotechnology-based products,
adverse effects of political or economical instability, major
hostilities or acts of terrorism on our significant worldwide
operations, interruptions in our supply chain or problems with our
information technology systems that adversely affect our complex
manufacturing processes, any failure to retain key personnel
(including Cephalon employees) or to attract additional executive
and managerial talent, the impact of continuing consolidation of
our distributors and customers, variations in patent laws that may
adversely affect our ability to manufacture our products in the
most efficient manner, potentially significant impairments of
intangible assets and goodwill, potential increases in tax
liabilities, the termination or expiration of governmental programs
or tax benefits, environmental risks and other factors that are
discussed in our Annual Report on Form 20-F for the year ended
December 31, 2012 and in our other filings with the U.S. Securities
and Exchange Commission. Forward-looking statements speak only as
of the date on which they are made and the Company undertakes no
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or
otherwise.